To penetrate solid tumors, low molecular weight (Mw< 10 KDa) compounds have an edge
over antibodies: their higher penetration because of their small size. Because of the dense …

Glioblastoma (GBM) is a lethal primary malignant brain tumor with no current effective
treatments. The recent emergence of immuno-virotherapy and FDA approval of T-VEC have …

Oncolytic viruses (OV) are viruses that can replicate selectively within cancer cells and
destroy them. While the past few decades have seen significant progress related to the use …

The cellular dispersion and therapeutic control of glioblastoma, the most aggressive type of
primary brain cancer, depends critically on the migration patterns after surgery and …

Oncolytic herpes simplex virus (oHSV) is a highly promising treatment for solid tumors.
Intense research and development efforts have led to first-in-class approval for an oHSV for …

The cellular dispersion and therapeutic control of glioblastoma, the most aggressive type of
primary brain cancer, depends critically on the migration patterns after surgery and …

Neutrophils display rapid and potent innate immune responses in various diseases. Tumor-
associated neutrophils (TANs) however either induce or overcome immunosuppressive …

This book explores outcome modeling in cancer from a data-centric perspective to enable a
better understanding of complex treatment response, to guide the design of advanced …

In a tumour microenvironment, tumour-associated neutrophils could display two opposing
differential phenotypes: anti-tumour (N1) and pro-tumour (N2) effector cells. Converting N2 …

Virotherapy treatment is a new and promising target therapy that selectively attacks cancer
cells without harming normal cells. Mathematical models of oncolytic viruses have shown …